NCT04147325

A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1

Virologic Response at 48 th Week, in Patients Newly Diagnosed With HIV-1, After the Implementation of a Test and Treat Model of Care, in a Single Portuguese Center.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 105 (actual)
• Sponsor: Janssen-Cilag Farmaceutica Ltda. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the proportion of newly diagnosed participants with Human Immunodeficiency Virus (HIV)-1 (naive participants) with virologic response at Week 48-defined as HIV-1 Ribonucleic acid (RNA) less than (\<) 50 copies/milliliter (mL) (Food And Drug Administration snapshot) - after the implementation of the Test \& Treat model of care and in a historical cohort.

Conditions

• HIV

Interventions

Type	Name	Description
DRUG	Antiretroviral Therapy	ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.

Timeline

• Start date: 2019-12-17
• Primary completion: 2022-12-12
• Completion: 2022-12-12
• First posted: 2019-11-01
• Last updated: 2023-12-11

Locations

1 site across 1 country: Portugal